Conservative management may be safe for retained central venous catheter fragments in children

Share :
Published: 24 Sep 2026
Views: 95
Rating:
Save
Dr Alessandro Crocoli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Dr Alessandro Crocoli speaks to ecancer about a 15-year retrospective study examining difficult central venous catheter removal in children.

He reports that difficult removal was rare, occurring in less than 1% of more than 3,000 procedures, and was particularly associated with prolonged catheter dwell times and chronic disease.

Dr Crocoli explains that almost half of the difficult cases resulted in a retained catheter fragment, with affected patients managed conservatively without subsequent late complications.

He highlights a shift from aggressive attempts at complete extraction towards a more conservative approach, suggesting that leaving retained intravascular fragments in place may be a safe option for selected asymptomatic patients when standard catheter removal fails.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

Dr Michele Milella - University of Verona, Verona, Italy
P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer ( Dr Michele Milella - University of Verona, Verona, Italy )
17 Jul 2026

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan
Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC ( Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan )
18 Mar 2026

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )
18 Dec 2025

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA
Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma ( Dr John Burke - Rocky Mountain Cancer Centers, Aurora, USA )
18 Dec 2025

IPSO guidelines on minimally invasive surgery in paediatric solid tumours

Dr Israel Fernandez-Pineda - Children’s Health Ireland at Crumlin, Dublin, Ireland
IPSO guidelines on minimally invasive surgery in paediatric solid tumours ( Dr Israel Fernandez-Pineda - Children’s Health Ireland at Crumlin, Dublin, Ireland )
19 Nov 2025

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma ( Dr Yelena Janjigian - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Oct 2025

Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations

Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden
Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations ( Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden )
14 Feb 2025

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Prof Robert Hills - University of Oxford, Oxford, United Kingdom
Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer ( Prof Robert Hills - University of Oxford, Oxford, United Kingdom )
18 Dec 2024

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA
Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )
17 Dec 2024